Cargando…

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction

Detalles Bibliográficos
Autores principales:	Nagata, Takuya, Ide, Tomomi, Tohyama, Takeshi, Kaku, Hidetaka, Enzan, Nobuyuki, Matsushima, Shouji, Ikeda, Masataka, Todaka, Koji, Tsutsui, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167497/ https://www.ncbi.nlm.nih.gov/pubmed/37181399 http://dx.doi.org/10.1016/j.jacasi.2022.11.013

Ejemplares similares

Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure
por: Tohyama, Takeshi, et al.
Publicado: (2021)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan　― Report From a National Registry of Clinical Personal Records ―
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Beta‐Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Electrocardiographic Left Ventricular Hypertrophy Is Independently Associated With Better Long-Term Outcomes in Dilated Cardiomyopathy Patients
por: Matsushima, Shouji, et al.
Publicado: (2019)

Propensity-Matched Study of Early Cardiac Rehabilitation in Patients With Acute Decompensated Heart Failure
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2022)

Blockade of L-type Ca(2+) channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway
por: Ikeda, Soichiro, et al.
Publicado: (2019)

IFN-γ-STAT1-ERK Pathway Mediates Protective Effects of Invariant Natural Killer T Cells Against Doxorubicin-Induced Cardiomyocyte Death
por: Sada, Masashi, et al.
Publicado: (2023)

The Prescription Pattern of Heart Failure Medications in Reduced, Mildly Reduced, and Preserved Ejection Fractions
por: Rastogi, Tripti, et al.
Publicado: (2022)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Iron Overload via Heme Degradation in the Endoplasmic Reticulum Triggers Ferroptosis in Myocardial Ischemia-Reperfusion Injury
por: Miyamoto, Hiroko Deguchi, et al.
Publicado: (2022)

ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
por: Pintér, Anita, et al.
Publicado: (2022)

Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction
por: Gao, Qian, et al.
Publicado: (2023)

Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States
por: Greene, Stephen J., et al.
Publicado: (2023)

Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
por: Escobar, Carlos, et al.
Publicado: (2022)

Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction
por: Nichols, Gregory A., et al.
Publicado: (2023)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Cryoballoon ablation for atrial fibrillation in patients with heart failure with mildly reduced and preserved ejection fraction
por: Chen, Chaofeng, et al.
Publicado: (2022)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Home‐based cardiac rehabilitation using information and communication technology for heart failure patients with frailty
por: Nagatomi, Yuta, et al.
Publicado: (2022)

Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain
por: Escobar, Carlos, et al.
Publicado: (2022)

Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort
por: Chen, Shiqun, et al.
Publicado: (2022)

Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis
por: Xiang, Boyang, et al.
Publicado: (2022)

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
por: Chatur, Safia, et al.
Publicado: (2023)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity
por: Tadokoro, Tomonori, et al.
Publicado: (2023)

Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
por: Rossitto, Giacomo, et al.
Publicado: (2020)

Combined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2022)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology
por: Urbancsek, Réka, et al.
Publicado: (2021)

Sex Differences in Heart Failure Mortality with Preserved, Mildly Reduced and Reduced Ejection Fraction: A Retrospective, Single-Center, Large-Cohort Study
por: Mansur, Antonio de Padua, et al.
Publicado: (2022)

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
por: Szabo, Timea Magdolna, et al.
Publicado: (2023)

Left Ventricular Noncompaction with Multiple Thrombi in Apical Aneurysm
por: Yakabe, Daisuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kc3e9cqfb89k2vnc6no8ecd4qe